T h e n e w e ng l a n d j o u r na l o f m e dic i n e n engl j med 368;25 nejm.org june 20, 2013 2386 A naplastic lymphoma kinase (ALK) is a validated tyrosine kinase target in several cancers, including non-small-cell lung cancer, anaplastic large-cell lymphoma, and pediatric neuroblastoma. [1] [2] [3] ALK rearrangements are found in approximately 5% of cases of nonsmall-cell lung cancer and define a distinct molecular subtype of lung cancer. [4] [5] [6] [7] With an estimated 1.3 million new cases of non-small-cell lung cancer worldwide each year, 8 this translates into more than 60,000 patients with ALK-positive non-small-cell lung cancer annually.
Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting ALK, MET, and ROS1 tyrosine kinases. 1, 9, 10 In two single-group studies, crizotinib showed marked antitumor activity in patients with advanced ALK-positive non-smallcell lung cancer, with objective response rates of approximately 60% and a median progression-free survival of 8.1 months in one of the studies and 9.7 months in the other. 11, 12 In contrast, standard single-agent chemotherapies in the general population of patients with non-small-cell lung cancer have been associated with response rates of 10% or lower and median progression-free survival of 2 to 3 months. [13] [14] [15] To date, the activity of standard chemotherapy has not been established in ALK-positive nonsmall-cell lung cancer. Retrospective studies suggest that ALK rearrangements may be associated with enhanced sensitivity to pemetrexed-based chemotherapy, with durations of response similar to those observed with crizotinib. 16, 17 We conducted a randomized, controlled, openlabel, phase 3 trial of crizotinib, as compared with standard chemotherapy in patients with advanced, previously treated ALK-positive non-small-cell lung cancer.
Me thods

Patients
Patients were eligible for inclusion in the study if they had locally advanced or metastatic non-smallcell lung cancer that was positive for ALK rearrangements. ALK testing was performed centrally with the use of a break-apart fluorescence in situ hybridization assay, which has an analytic sensitivity of 100% (95% confidence interval [CI] , 98 to 100) and specificity of 100% (95% CI, 97 to 100). 1 Other eligibility criteria included an age of at least 18 years, progressive disease after one prior platinum-based chemotherapy regimen, measurable disease as assessed with the use of Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, 18 and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (with 0 indicating that the patient is fully active, 1 that the patient is ambulatory but restricted in strenuous activity, and 2 that the patient is ambulatory and capable of self-care but is unable to work 19 ). Patients with stable brain metastases that had been treated previously or were untreated and asymptomatic were eligible. All patients provided written informed consent.
Study Oversight
The protocol was approved by the institutional review board or independent ethics committee at each participating site and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. The study was designed by the sponsor (Pfizer) together with the members of the PROFILE 1007 steering committee (see the Supplementary Appendix, available with the full text of this article at NEJM.org). The sponsor collected the data and analyzed them in conjunction with the authors. The corresponding author wrote all the drafts of the manuscript. All the authors made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data and for the fidelity of this report to the study protocol. Editorial support was provided by a medical writer at ACUMED (New York), who was funded by the sponsor. The protocol and statistical analysis plan are available at NEJM.org.
Study Design and Treatment
Patients were randomly assigned, in a 1:1 ratio, to receive oral crizotinib (250 mg twice daily) in a 3-week cycle or intravenous chemotherapy comprising either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks. Patients who were randomly assigned to chemotherapy received pemetrexed unless their prior chemotherapy regimen contained pemetrexed or unless their tumor had predominantly squamous-cell histologic features. Patients were stratified according to ECOG performance status (0 or 1 vs. 2), the presence or absence of brain metastases, and prior or no prior therapy with epidermal growth factor receptor (EGFR) kinase inhibitors.
The primary end point was progression-free survival, as assessed by independent radiologic review. Secondary end points included overall survival, response rate (rate of partial and complete responses), safety, and patient-reported outcomes. Treatment was continued until RECIST-defined disease progression was documented, unacceptable toxic effects developed, the patient withdrew from the study, or the patient died. Patients could continue treatment beyond RECIST-defined progression at the discretion of the investigator. Patients in the chemotherapy group with RECISTdefined progression were allowed to cross over to receive crizotinib as part of a separate study (ClinicalTrials.gov number, NCT00932451).
Assessments
Patients underwent baseline tumor imaging, including brain and bone scanning. Tumor assessments were performed every 6 weeks until RECISTdefined disease progression. RECIST, version 1.1, was used to assess tumor responses; all scans were subject to central review by independent radiologists who were unaware of the group assignments. Adverse events, which were classified and graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (http://evs.nci .nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf), were assessed from the time the patient provided written informed consent until at least 28 days after the last dose of study drug was administered. Patient-reported symptoms, functioning, and global quality of life were assessed at baseline, on day 1 of every cycle, and at the end of treatment with the use of a validated questionnaire, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (QLQ-C30) 20 and its corresponding module for lung cancer (QLQ-LC13). 21 Scores on these questionnaires range from 0 to 100. For symptoms, higher scores indicate greater severity of symptoms; for global quality of life, higher scores indicate better global quality of life.
Statistical Analysis
We estimated that with a total of 217 progression events or deaths, the study would have 90% power to detect a 56% improvement in progressionfree survival with crizotinib as compared with chemotherapy (i.e., median progression-free survival of 7.0 months vs. 4.5 months), at a one-sided alpha level of 0.025. Progression-free survival was defined as the time from randomization to progression of the disease, as assessed by means of independent radiologic review, or to death. The prespecified number of progression events or deaths was reached in March 2012; the date of data cutoff was March 30, 2012 . One prespecified interim analysis of overall survival was performed at the time of the final analysis of progressionfree survival. For the final survival analysis, we estimate that 241 events will be required for the study to have 80% power to detect a 44% increase in overall survival; this number of events is not projected to occur until 21 months after the time of data cutoff.
Efficacy end points were analyzed mainly in the intention-to-treat population. We used the Kaplan-Meier method to estimate progressionfree survival and overall survival, one-sided stratified log-rank tests to compare survival curves between the two groups, and stratified Cox regression models to estimate hazard ratios. Response rates as assessed by means of independent radiologic review were compared between the treatment groups with the use of a two-sided stratified Cochran-Mantel-Haenszel test. We evaluated efficacy end points for pemetrexed and docetaxel separately in the as-treated population, which included patients who received at least one dose of study medication.
Patient-reported outcomes were evaluated in all treated patients who had completed a baseline assessment and at least one post-baseline assessment. Repeated-measures mixed-effects modeling was performed to compare the two groups with respect to the overall change from baseline scores on the QLQ-C30 and QLQ-LC13 scales. The time to deterioration was calculated as the time from randomization to the first increase of 10 points or more (indicating worsening condition) from baseline in scores for a composite end point of chest pain, dyspnea, or cough. The time to deterioration was estimated with the use of the Kaplan-Meier method and was compared between the two groups with the use of an unstratified log-rank test. domization comprised the intention-to-treat population. A total of 99 patients (57%) in the chemotherapy group received pemetrexed, and 72 (41%) received docetaxel. Three patients who were randomly assigned to the chemotherapy group and 1 who was randomly assigned to the crizotinib group did not receive the assigned study treatment.
At the time of data cutoff, the median follow-up for overall survival was 12.2 months in the crizotinib group and 12.1 months in the chemotherapy group. The baseline characteristics of the patients were well balanced between the two study groups ( Table 1) . The majority of patients were younger than 65 years of age, had never smoked, and had adenocarcinoma of the lung -characteristics that were consistent with those of patients with ALK-positive non-small-cell lung cancer in prior studies. 22, 23 The baseline characteristics of the patients according to the type of chemotherapy they received are shown in Table S1 in the Supplementary Appendix.
Efficacy
Among the 347 patients in the intention-to-treat population, 227 had disease progression or died by the time of data cutoff. The median progression-free survival, as determined by independent radiologic review, was 7.7 months (95% CI, 6.0 to 8.8) in the crizotinib group, as compared with 3.0 months (95% CI, 2.6 to 4.3) in the chemotherapy group (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001) (Fig. 1A) . In subgroup analyses, there was significant improvement in progression-free survival with crizotinib as compared with pemetrexed (hazard ratio for disease progression or death, 0.59; 95% CI, 0.43 to 0.80; P<0.001) and as compared with docetaxel (hazard ratio for disease progression or death, 0.30; 95% CI, 0.21 to 0.43; P<0.001) (Fig. 1B) . Progression-free survival was longer with crizotinib than with chemotherapy in patient subgroups defined according to baseline characteristics and stratification factors (Fig. S2 in the Supplementary Appendix).
In the intention-to-treat population, the response rate, as verified by means of independent radiologic review, was significantly higher in the crizotinib group than in the chemotherapy group: 65% (95% CI, 58 to 72) with crizotinib as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001) ( Table 2 ). In the as-treated population, the response rate was higher with crizotinib than with either type of chemotherapy (Fig. S3 in the Supplementary Appendix): 66% (95% CI, 58 to 73) with crizotinib, as compared with 29% (95% CI, 21 to 39) with pemetrexed and 7% (95% CI, 2 to 16) with docetaxel. All the * There were no significant differences between the groups in any of the baseline characteristics listed here. † Race was reported by the investigators. ‡ Data were missing for one patient in the crizotinib group. § Data were missing for seven patients: four in the crizotinib group and three in the chemotherapy group. ¶ An Eastern Cooperative Oncology Group (ECOG) performance status of 0 indicates that the patient is fully active, 1 that the patient is ambulatory but restricted in strenuous activity, and 2 that the patient is ambulatory and capable of self-care but is unable to work. Data were missing for one patient in the crizotinib group. differences in response rates between crizotinib and each type of chemotherapy were significant (P<0.001).
At the time of data cutoff, 96 deaths had occurred in the intention-to-treat population -49 (28%) in the crizotinib group and 47 (27%) in the chemotherapy group -representing 40% of the total number of events required for the final analysis of overall survival. The median overall survival was 20.3 months (95% CI, 18.1 to not reached) with crizotinib and 22.8 months (95% CI, 18.6 to not reached) with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54) (Fig. S4 in the Supplementary Appendix). Of the 174 patients who were randomly assigned to chemotherapy, 112 (64%) subsequently received crizotinib outside the study; 34 patients (20%) discontinued chemotherapy but did not receive crizotinib, including 13 patients who died either while receiving chemotherapy or before starting follow-up therapy (Table S2 in the Supplementary Appendix).
A total of 85 patients (49%) in the crizotinib group and 28 patients (16%) in the chemotherapy group were still receiving the study treatment at the time of data cutoff. More patients in the crizotinib group than in the chemotherapy group continued treatment beyond RECIST-defined progression of disease (58 vs. 17), and the duration of such therapy was longer with crizotinib than with chemotherapy (median, 15.9 weeks [range, 2.9 to 73.4] vs. 6.9 weeks [range, 6.0 to 42.0]).
Safety and Adverse Events
A total of 343 patients (the as-treated population) were included in the safety analysis. This analysis was not adjusted for the fact that patients in the crizotinib group received the assigned treatment for a longer duration than did patients in the chemotherapy group (median, 31 weeks vs. 12 weeks). The most common adverse events with crizotinib for which the incidence was at least 5% greater than that observed with chemotherapy were vision disorder (most frequently, visual impairment, photopsia, or blurred vision), diarrhea, nausea, vomiting, constipation, elevated liver aminotransferase levels, edema, upper respiratory infection, dysgeusia, and dizziness (Table 3) . These events were mostly grade 1 or 2, with the exception of elevated aminotransferase levels, which were grade 3 or 4 in 27 patients (16%). The most common adverse events with chemotherapy for which the incidence was at least 5% greater than that observed with crizotinib were fatigue, alopecia, dyspnea, and rash (Table 3) .
In the crizotinib group, grade 3 or 4 neutropenia occurred in 23 patients (13%), including 1 patient who had febrile neutropenia (Table S3 in the Supplementary Appendix). In the chemotherapy group, grade 3 or 4 neutropenia occurred in 33 patients (19%), including 16 patients who had febrile neutropenia. Panel A shows Kaplan-Meier estimates of progression-free survival in the intention-to-treat population. The median progression-free survival was 7.7 months with crizotinib as compared with 3.0 months with chemotherapy. Panel B shows Kaplan-Meier estimates of progression-free survival in the as-treated population (which excluded four patients who did not receive study treatment), according to the type of chemotherapy. The median progression-free survival was 7.7 months with crizotinib, as compared with 4.2 months with pemetrexed and 2.6 months with docetaxel. In both panels, tick marks on the survival curves indicate censoring of data. By the time of data cutoff, 25 patients (15%) in the crizotinib group and 7 (4%) in the chemotherapy group had died from any cause during the course of the study (Table S4 in the Supplementary Appendix). The most common cause of death in both groups was disease progression, which was reported in 14 patients in the crizotinib group and 3 in the chemotherapy group. Treatment-related deaths occurred in 3 patients in the crizotinib group (with the death due to ventricular arrhythmia in 1 patient and to interstitial lung disease or pneumonitis in 2 patients), and in 1 patient in the chemotherapy group (with the death due to sepsis). In addition, in the crizotinib group, hepatic dysfunction meeting the criteria for Hy's law (a serum bilirubin level ≥3 times the upper limit of the normal range in the absence of biliary obstruction or Gilbert's syndrome) 24 developed in 1 patient, who subsequently died of hepatic failure after the data cutoff date.
The New England
Overall, more adverse events of any cause were reported in the crizotinib group than in the chemotherapy group. This increase in all-cause adverse events was still apparent after events that occurred after RECIST-defined disease progression were excluded (Table S5 in the Supplementary Appendix). The incidence of treatmentrelated grade 3 or 4 adverse events was similar in the two groups (33% with crizotinib and 32% with chemotherapy), as was the incidence of treatmentrelated serious adverse events (12% and 14% in the two groups, respectively). Treatment-related adverse events leading to permanent discontinuation of the study drug occurred in 6% and 10% of patients in the two groups, respectively.
Patient-Reported Outcomes
Baseline scores on the QLQ-C30 and QLQ-LC13 are summarized in Table S6 in the Supplementary Appendix. There was a significantly greater overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, chest pain, arm or shoulder pain, and pain in other parts of the body with crizotinib than with chemotherapy (P<0.001 for all comparisons, without adjustment for multiple testing) ( Fig. 2A) . Patients treated with crizotinib also had a significantly greater delay in the worsening of symptoms. The median time to deterioration with respect to a composite end point of three symptoms -cough, dyspnea, or chest pain -was 5.6 months with crizotinib, as compared with 1.4 months with chemotherapy (hazard ratio with crizotinib, 0.54; 95% CI, 0.40 to 0.71; P<0.001) (Fig. 2B) .
There was also a significantly greater overall improvement from baseline in global quality of life among patients who received crizotinib treatment than among those who received chemotherapy (P<0.001) (Fig. 2A) . In particular, in the crizotinib group a statistically significant and clinically meaningful (≥10-point) improvement from baseline in global quality of life was observed in cycle 4, and a statistically significant (although <10-point) improvement from baseline in global quality of life was observed in cycles 2 through 12 and cycle 14. In contrast, in the chemotherapy group, no significant change from baseline in global quality of life was observed at any time point. Similarly, in all domains measuring functioning, except for the domain measuring cognitive functioning, there was a significantly greater overall improvement from baseline among patients in the crizotinib group than among patients in the chemotherapy group (Fig. S5 in the Supplementary Appendix).
Discussion
We conducted a prospective, randomized, phase 3 trial comparing crizotinib therapy with standard chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer. As compared with standard second-line chemotherapy, treatment with crizotinib resulted in significantly longer progression-free survival, significantly higher response rates, a significant reduction in symptoms, and a significant improvement in global quality of life. In this study, crizotinib was more effective than either pemetrexed or docetaxel. The efficacy of second-line docetaxel in patients with ALK-positive non-small-cell lung cancer was modest, a finding that was consistent with that in previous studies involving the general population of patients with non-small-cell lung cancer. 13, 15 In contrast, the response rate to pemetrexed was higher than expected -29%, as compared with 12.8% in the general population of patients with lung adenocarcinoma who had previously been treated with chemotherapy 13, 25 -though the median progression-free survival among patients in our study who received pemetrexed was only 4.2 months. Thus, patients with ALK-positive non-small-cell lung cancer may have a higher response rate with pemetrexed than does the general population with non-small-cell lung cancer. However, the benefit of pemetrexed is less than that originally suggested in retrospective studies 16, 17 and, importantly, less than that of crizotinib, as shown in this randomized trial.
In a prespecified interim analysis, overall survival was shown to be similar in the crizotinib and chemotherapy groups. This analysis was immature, and it is likely that it was confounded by the high crossover rate among patients in the chemotherapy group. Crossover has similarly complicated the analysis of overall survival in other randomized, phase 3 studies of EGFR kinase inhibitors in patients with advanced EGFRmutant non-small-cell lung cancer. [26] [27] [28] Despite these limitations, the median overall survival among patients in this study from the time that second-line therapy was initiated was remarkably high, at longer than 20 months, suggesting that the addition of crizotinib either before or after second-line chemotherapy may contribute to improving survival. In contrast, in a small retrospective study, the median overall survival from the time of initiation of second-line therapy among patients with ALK-positive non-small-cell lung cancer who had not received crizotinib was 6 months. 29 Both crizotinib and chemotherapy were associated with toxic effects that were primarily grade 1 or 2. Two important toxic effects that were associated with crizotinib were elevated aminotransferase levels and interstitial lung disease. Treatment-related elevation of aminotransferase levels of any grade was reported in 66 patients (38%) in the crizotinib group, including 27 (16%) with grade 3 or 4 elevated levels; in 1 patient, concurrent elevations in bilirubin levels not related to cholestasis progressed to fatal hepatic failure. In two earlier studies of crizotinib, the incidence of elevated aminotransferase levels of grade 3 or 4 were lower, at 7% and 9%. 11, 12 Although interstitial lung disease is much less common than elevated aminotransferase levels, it is a known and worrisome adverse event associated with crizotinib. In this study, 3 patients in the crizotinib group (2%) had treatment-related interstitial lung disease of grade 3 or higher; two of the cases were fatal. Across all crizotinib studies, including this one, 11,12 the estimated incidence of treatment-related interstitial lung disease of grade 3 or higher is 1%, an incidence similar to that reported with EGFR kinase inhibitors in clinical studies. 30 Although the incidence of treatment-related serious adverse events was similar in the crizotinib and chemotherapy groups, significantly more adverse events of any cause were observed in the crizotinib group. Two factors may have contributed to this finding. First, the duration of study treatment was significantly longer with crizotinib than with chemotherapy, and the safety analysis was not adjusted to take into account this difference in treatment durations. Second, significantly more patients in the crizotinib group continued treatment beyond RECIST-defined progression of disease, and the duration of such therapy was longer with crizotinib than with chemotherapy. These differences may have resulted in an imbalance between the two groups that could account in part for the increased incidence of all-cause adverse events seen with crizotinib (Table S5 in the Supplementary Appendix) .
In conclusion, this study showed that crizotinib, as compared with chemotherapy, prolonged progression-free survival, increased response rates, and improved the quality of life in patients with advanced, previously treated ALK-positive nonsmall-cell lung cancer. The apparent lack of a survival benefit probably reflects the confounding effects of crossover, effects that have been observed in other randomized trials of molecularly targeted agents in patients with non-small-cell lung cancer.
